OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background: Chronic migraine (CM) is associated with high impact and reduced health-related quality of life (HRQoL). Methods: Patients with CM from PREEMPT (Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy) were randomized (1:1) to receive onabotulinumtoxinA or placebo for two 12-week cycles in the double-blind (DB) phase, followed by three 12-week cycles of open-label (OL) onabotulinumtoxinA (onabotulinumtoxinA/onabotulinumtoxinA (O/O) and placebo/onabotulinumtoxinA (P/O) groups, respectively). HRQoL endpoints were assessed over 56 weeks using the Headache Impact Test (HIT-6) and the Migraine-Specific Quality of Life Questionnaire (MSQ). HIT-6 score reductions ≥2.3 and ≥5 denoted between-group minimally important difference and within-patient clinically meaningful response, respectively. Results: A total of 1236 participants (O/O, n = 607; P/O, n = 629) participated in both phases. The DB phase showed significantly reduced HIT-6 and MSQ for onabotulinumtoxinA versus placebo (all p < 0.001). The OL phase showed significantly reduced HIT-6 for O/O versus P/O at weeks 28, 36, and 48, but not 56. All three MSQ domains showed improved HRQoL relative to baseline, but only the role restrictive domain showed a significant difference between O/O and P/O at week 56. Conclusions: Benefits of onabotulinumtoxinA on HRQoL versus baseline persisted throughout the OL phase. Statistical superiority in favor of O/O was demonstrated for HIT-6 through 48 weeks and for MSQ (role restrictive) at 56 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
The International Classification of Headache Disorders: 2nd edition
Olesen, J., Goadsby, P., & Steiner, T. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00590-8 · Cited by 5,049
Olesen, J. (2004) · Cephalalgia · doi:10.1111/j.1468-2982.2003.00824.x · Cited by 2,056
A six-item short-form survey for measuring headache impact: The HIT-6™
Kosinski, M., Bayliss, M. S., Bjorner, J. B., Ware, J. E., Garber, W. H., Batenhorst, A., Cady, R., Dahlöf, C. G. H., Dowson, A., & Tepper, S. (2003) · Quality of Life Research · doi:10.1023/a:1026119331193 · Cited by 1,376 · cited 1×
“The validated HIT-6 is a self-administered tool that assesses the impact of headache using widely measured, functionally relevant domains: pain, social and role limitations, cognitive functioning, vitality, and psychological distress (12,13).”
MethodAurora, S., Dodick, D., Turkel, C., DeGryse, R., Silberstein, S., Lipton, R., Diener, H., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364676 · Cited by 1,047 · cited 4×
“Primary results from the 24-week, double-blind phase have been published separately for PREEMPT 1 (6) and PREEMPT 2 (7).”
BackgroundMethodInfluentialSelf-citationDodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., Diener, H., & Brin, M. F. (2010) · Headache: The Journal of Head and Face Pain · doi:10.1111/j.1526-4610.2010.01678.x · Cited by 994 · cited 2×
“Data from the two trials were subsequently pooled to examine the durability and precision of the individual study results and to explore other potentially relevant findings by virtue of the added statistical power (8,9).”
MethodSelf-citationDiener, H., Dodick, D., Aurora, S., Turkel, C., DeGryse, R., Lipton, R., Silberstein, S., & Brin, M. (2010) · Cephalalgia · doi:10.1177/0333102410364677 · Cited by 960 · cited 4×
“Primary results from the 24-week, double-blind phase have been published separately for PREEMPT 1 (6) and PREEMPT 2 (7).”
BackgroundMethodInfluentialSelf-citationNew Appendix Criteria Open for a Broader Concept of Chronic Migraine
Olesen, J., Bousser, M.-G., Diener, H.-C., Dodick, D., First, M., Goadsby, P., Göbel, H., Lainez, M., Lance, J., Lipton, R., et al. (2006) · Cephalalgia · doi:10.1111/j.1468-2982.2006.01172.x · Cited by 909
Self-citationGlobal prevalence of chronic migraine: A systematic review
Natoli, J., Manack, A., Dean, B., Butler, Q., Turkel, C., Stovner, L., & Lipton, R. (2010) · Cephalalgia · doi:10.1111/j.1468-2982.2009.01941.x · Cited by 693 · cited 1×
“Variation in case definition contributes to the varying estimates of CM prevalence (ranging from 0 to 5%) in epidemiologic studies (27).”
BackgroundSelf-citationBlumenfeld, A., Varon, S., Wilcox, T., Buse, D., Kawata, A., Manack, A., Goadsby, P., & Lipton, R. (2011) · Cephalalgia · doi:10.1177/0333102410381145 · Cited by 627 · cited 2×
“Individuals with CM experience greater headache impact (1) and disability (2), reduced productivity at work, home, and school (3), decreased health-related quality of life (HRQoL) (1), and increased comorbid medical conditions, including obesity, vascular disease, and psychiatric disorders (1,2,4) compared with those…”
BackgroundSelf-citation
Research works printed but not linked: 1
- Bayliss MS, 2002, The HIT-6™: A user’s guide
Cited by
Tassorelli, C., Diener, H.-C., Dodick, D. W., Silberstein, S. D., Lipton, R. B., Ashina, M., Becker, W. J., Ferrari, M. D., Goadsby, P. J., Pozo-Rosich, P., et al. (2018) · Cephalalgia · doi:10.1177/0333102418758283 · Cited by 388
“For chronic migraine, there are no disease-specific instruments, but the instruments used for episodic migraine have performed well in capturing the impact of chronic migraine (71).”
Self-citationBendtsen, L., Sacco, S., Ashina, M., Mitsikostas, D. D., Ahmed, F., Pozo‐Rosich, P., & Martelletti, P. (2018) · The Journal of Headache and Pain · doi:10.1186/s10194-018-0921-8 · Cited by 163
Botulinum toxins for the prevention of migraine in adults
Herd, C. P., Tomlinson, C. L., Rick, C., Scotton, W. J., Edwards, J. A., Ives, N. J., Clarke, C. E., & Sinclair, A. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011616.pub2 · Cited by 149
Erenumab (AMG 334) in episodic migraine
Ashina, M., Dodick, D. W., Goadsby, P. J., Reuter, U., Silberstein, S. D., Zhang, F., Gage, J. R., Cheng, S., Mikol, D. D., & Lenz, R. A. (2017) · Neurology · doi:10.1212/wnl.0000000000004391 · Cited by 134
Pregabalin as a Pain Therapeutic: Beyond Calcium Channels
Alles, S. R. A., Cain, S. M., & Snutch, T. P. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00083 · Cited by 141
“Interestingly, onabotulinumtoxin A is effective as a therapy for the treatment of chronic migraine, which is characterized by a headache frequency of 15 episodes per month or more (Frampton, 2012; Lipton et al., 2016).”
Background
Metadata
- Authors
- Lipton, R. B., Rosen, N. L., Ailani, J., DeGryse, R. E., Gillard, P. J., & Varon, S. F.
- Affiliations
- Albert Einstein College of Medicine (US)
- Northwell Health (US)
- Georgetown University (US)
- Allergan plc, Irvine, CA, USA
- Corresponding author
- Lipton, Richard B
- Venue
- Cephalalgia
- Publisher
- SAGE Publications
- Published
- 2016-06-10
- Volume
- 36
- Issue
- 9
- Pages
- 899-908
- ISSN
- 0333-1024 (ISSN-L)
- 1468-2982
- PMC
- PMC4959035
- OpenAlex
- W2417058223
- Cited by
- 85
- References
- 29
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 10 · 2023: 7 · 2022: 5 · 2021: 6 · 2020: 15 · 2019: 5 · 2018: 16 · 2017: 10 · 2016: 4
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Cephalalgia (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Teva Pharmaceutical Industries
- National Institutes of Health
- Allergan
- Topics
- Health Sciences › Medicine › Clinical Neurology › Migraine and Headache Studies
- Health Sciences › Dentistry › Oral Surgery › Temporomandibular Joint Disorders
- Health Sciences › Medicine › Clinical Neurology › Botulinum Toxin and Related Neurological Disorders
- Keywords
- onabotulinumtoxinA, chronic migraine, health-related quality of life, migraine-specific quality of life, HIT-6, Migraine-Specific Quality of Life Questionnaire, migraine prophylaxis, PREEMPT trial, long-term treatment outcomes
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Male, Middle Aged, Migraine Disorders, Neuromuscular Agents, Treatment Outcome, Botulinum Toxins, Type A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program. https://app.cochat.ai/papers/10.1177/0333102416652092
- The paper
- Lipton, R. B., Rosen, N. L., Ailani, J., DeGryse, R. E., Gillard, P. J., & Varon, S. F. (2016). OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program. Cephalalgia. https://doi.org/10.1177/0333102416652092
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.